好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A Phase 3 Study to Evaluate ISIS-TTRRx in Patients with Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP): Study Design and Baseline Demographics
General Neurology
(-)
006
Authors/Disclosures
Merrill Benson
PRESENTER
No disclosure on file
John C. Kincaid, MD, FAAN (Indiana University) Dr. Kincaid has received personal compensation in the range of $500-$4,999 for serving as a Consultant for strongbridge pharmaceuticals. Dr. Kincaid has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for social security administrstion. The institution of Dr. Kincaid has received research support from Ionis Pharmaceuticals. Dr. Kincaid has received publishing royalties from a publication relating to health care. Dr. Kincaid has received personal compensation in the range of $500-$4,999 for serving as a medical expert for disability cases with social security administrstion. Dr. Kincaid has a non-compensated relationship as a I am the historian of the Board of Directors for this organization with AANEM that is relevant to AAN interests or activities.
Elizabeth Ackermann, PhD (ISIS PHARMACEUTICALS, INC) No disclosure on file
Brett Monia, PhD (Ionis Pharmaceuticals) No disclosure on file
Emmanuelle Waubant, MD, PhD, FAAN (USCF MS Center) The institution of Dr. Waubant has received research support from NIH. The institution of Dr. Waubant has received research support from NMSS. The institution of Dr. Waubant has received research support from PCORI. The institution of Dr. Waubant has received research support from Race to Erase MS. The institution of Dr. Waubant has received research support from Roche. The institution of Dr. Waubant has received research support from Department of Defense. Dr. Waubant has received publishing royalties from a publication relating to health care.
No disclosure on file